Search results for "Combined"

showing 10 items of 1205 documents

Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.

2017

Abstract Background The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects. Purpose There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens. Study design In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants. Results The combination of erlotinib with artesunate leads to synergistic inhibition of cell grow…

0301 basic medicineCombination therapymedicine.medical_treatmentPharmaceutical ScienceArtesunateDrug resistancePharmacology03 medical and health scienceschemistry.chemical_compoundErlotinib Hydrochloride0302 clinical medicineIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansEpidermal growth factor receptorMolecular Targeted TherapyProtein Kinase InhibitorsPharmacologyChemotherapybiologybusiness.industryCancermedicine.diseaseArtemisininsErbB Receptors030104 developmental biologyComplementary and alternative medicinechemistryArtesunate030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibbusinessmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Could lymphadenectomy be avoided in locally advanced cervical cancer patients administered preoperative chemoradiation? A large-scale retrospective s…

2017

Abstract Introduction To identify a subset of cervical cancer (CC) patients administered chemoradiation (CT/RT) plus radical surgery (RS), who can be spared lymphadenectomy, and complications. Patients and methods 430 Stage IB2-IIB patients without LN involvement at imaging were accrued (March 1996–December 2015) at Gynecologic Oncology Unit of the Catholic University of Rome/Campobasso. CT/RT consisted of pelvic irradiation plus cisplatin based chemotherapy. Objective response was evaluated according to RECIST criteria; radical hysterectomy and pelvic ± aortic lymphadenectomy was attempted in patients achieving response or stable disease. Surgical morbidity was classified according to the …

0301 basic medicineComplicationsmedicine.medical_treatmentRadical surgeryUterine Cervical Neoplasms0302 clinical medicineCervical cancer Chemoradiation Aged 80 and over Antineoplastic Agents Cisplatin Combined Modality Therapy Female Humans Hysterectomy Middle Aged Neoplasm Staging Retrospective Studies Treatment Outcome Uterine Cervical Neoplasms Chemoradiotherapy Lymph Node Excision Lymphadenectomy Radical surgery80 and overMedicineStage (cooking)Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAAged 80 and overCervical cancerChemoradiotherapyGeneral MedicineMiddle AgedCombined Modality TherapyLymphovascularTreatment Outcomemedicine.anatomical_structureChemoradiationOncologyCervical cancer; Chemoradiation; Complications; Lymphadenectomy; Radical surgery; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Chemoradiotherapy; Lymph Node Excision; Surgery; Oncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtyAntineoplastic AgentsGynecologic oncologyHysterectomy03 medical and health sciencesHumansRadical surgeryRadical HysterectomyCervixAgedNeoplasm StagingRetrospective Studiesbusiness.industryLymphadenectomymedicine.diseaseSurgery030104 developmental biologyCervical cancerLymph Node ExcisionSurgeryLymphadenectomyCervical cancer; Chemoradiation; Complications; Lymphadenectomy; Radical surgery; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Chemoradiotherapy; Lymph Node ExcisionCisplatinbusinessEuropean Journal of Surgical Oncology
researchProduct

Cancer combination therapies with artemisinin-type drugs

2017

Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents an…

0301 basic medicineDrugCombination therapymedicine.medical_treatmentmedia_common.quotation_subjectArtemisia annuaDrug resistancePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoCell Line TumorNeoplasmsAntineoplastic Combined Chemotherapy Protocolsparasitic diseasesmedicineAnimalsHumansDrug InteractionsArtemisininmedia_commonPharmacologyBiological ProductsChemotherapyNatural productbiologybusiness.industryDrug SynergismDrugs Investigationalbiology.organism_classificationAntineoplastic Agents PhytogenicCombined Modality TherapyArtemisininsDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisChemical and Drug Induced Liver InjurybusinessSesquiterpenesmedicine.drugBiochemical Pharmacology
researchProduct

Monitoring of rheologic variables during postoperative high-dose brachytherapy for uterine cancer.

2004

Oxygenation of tumor tissue has recently been assed an important prerequisite for the effectiveness of radiotherapy in cervical cancer. Hyperviscosity is a common phenomenon in malignancy and a cause of reduced oxygen transport capacity that would favour tissue hypoxia. Hemorheological variables were serially tested preoperatively, during four cycles of fractionated adjuvant IR192 HDR after loading radiation (HDR-AL) of the vaginal vault (weekly intervals), and 6 months postoperatively in patients with cervical (n=12) and endometrial cancer (n=26). Women who were scheduled for benign tumor surgery served as controls (n=29). Preoperatively, in cervical and endometrial cancer patients, mean …

0301 basic medicineErythrocyte Aggregationmedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyUrologyUterine Cervical Neoplasms030204 cardiovascular system & hematologyHysterectomy03 medical and health sciencesLeukocyte Count0302 clinical medicineUterine cancermedicineHumansAgedCervical cancerbusiness.industryPlatelet CountEndometrial cancerOxygen transportFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood ViscosityCombined Modality TherapyCell HypoxiaSurgeryEndometrial NeoplasmsRadiation therapy030104 developmental biologyHemorheologyVaginal vaultFemaleRadiotherapy AdjuvantbusinessBiomarkersClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells

2021

Cancer stem cells (CSCs) are the tumor cell subpopulation responsible for resistance to chemotherapy, tumor recurrence, and metastasis. An efficient therapy must act on low proliferating quiescent-CSCs (q-CSCs). We here investigate the effect of magnetic hyperthermia (MHT) in combination with local chemotherapy as a dual therapy to inhibit patient-derived colorectal qCR-CSCs. We apply iron oxide nanocubes as MHT heat mediators, coated with a thermoresponsive polymer (TR-Cubes) and loaded with DOXO (TR-DOXO) as a chemotherapeutic agent. The thermoresponsive polymer releases DOXO only at a temperature above 44 °C. In colony-forming assays, the cells exposed to TR-Cubes with MHT reveal that qC…

0301 basic medicineHyperthermiacancer stem cellsmagnetic nanoparticlesMaterials scienceSettore MED/50 - Scienze Tecniche Mediche Applicatecolorectal cancerdoxorubicinMetastasis03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivoCancer stem cellmedicineHumansGeneral Materials ScienceDoxorubicinmagnetic hyperthermiaMagnetite NanoparticlesAntibiotics AntineoplasticHyperthermia Inducedmedicine.diseaseCombined Modality Therapy3. Good healthOxaliplatin030104 developmental biology030220 oncology & carcinogenesisDrug deliveryCancer researchNeoplastic Stem CellsStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioColorectal Neoplasmsmedicine.drugResearch Article
researchProduct

Danger signals: Chemotherapy enhancers?

2017

IF 9.614; International audience; Endogenous danger signals are molecules normally present in a given cell compartment that are rapidly released following cell stress and induce immune responses. We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, which rely on their release of danger signals such as the nuclear protein HMGB1. DNA can also be released from chemotherapy-treated tumor cells, act as a danger signal, and boost anticancer immunity. While the immunostimulatory properties of DNA have been identified for decades, the recent discovery of a novel family of receptors, cytosolic DNA sensors, has provided a nov…

0301 basic medicineImmunologyCelleducationBiologyHMGB1CD8+ T cellschemotherapyCancer Vaccines03 medical and health sciences0302 clinical medicineImmune systemDrug TherapyNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumanscancer[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMolecular Targeted TherapyNuclear proteinHMGB1 ProteinReceptorinnate immunityInnate immune systemDNAadaptive immunityAcquired immune systemCombined Modality TherapyImmunity Innate3. Good health030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunotherapy030215 immunologySignal TransductionSTINGImmunological Reviews
researchProduct

Potential Therapeutic Applications of MDA-9/Syntenin-NF-κB-RKIP Loop in Human Liver Carcinoma

2019

Background Overexpression of MDA-9/Syntenin occurs in multiple human cancer cell lines and is associated with higher grade of tumor classification, invasiveness and metastasis. In some cases, its role in cancer biology depends on relationships between MDA-9/Syntenin and NF-κB. Objective This study aims to analyze the presence of a regulation loop like that between MDA-9/Syntenin - NF-κB - RKIP in human liver carcinoma. Methods Transient transfection was performed with siRNA anti-MDA-9/Syntenin. Expression of different factors was evaluated by Real time-PCR and Western blotting, while NF-κB activation by TransAM assay. Invasion capacity was analyzed by Matrigel Invasion Assay and the effects…

0301 basic medicineMDA-9/Syntenin NF-κB RKIP drug targets HA22T/VGH Hep3B HepG2Carcinoma HepatocellularCurcuminSynteninsPhosphatidylethanolamine Binding ProteinBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationAntineoplastic Combined Chemotherapy ProtocolsHumansGene silencingNeoplasm InvasivenessViability assayMolecular BiologyCell growthMatrigel Invasion AssayLiver NeoplasmsNF-kappa BNF-κBHep G2 CellsGeneral MedicineNeoplasm ProteinsBlot030104 developmental biologychemistryDoxorubicinCell cultureSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineSignal Transduction030215 immunologyCurrent Molecular Medicine
researchProduct

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.

2016

Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS and a key mediator of oxidative cardiac damage. The impact of NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112, RAC2:rs13058338) was evaluated in 225 adult de novo AML patients. Variant alleles of NCF4 and RAC2 were related to higher complete remission (P=0.035, P=0.016), and CYBA homozygous variant showed lower overall survival with recessive model (P=0.045). Anthracycline-induced cardiotoxicity was associated to NCF4 homozygous variant (P=0.012) and CYBA heterozygous genotype (P=0.027). Novel associations…

0301 basic medicineMaleAnthracyclinePharmacologyBiologyPolymorphism Single NucleotideNephrotoxicity03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsHumansAgedRetrospective StudiesPharmacologychemistry.chemical_classificationReactive oxygen speciesCardiotoxicityNADPH oxidaseRemission InductionMyeloid leukemiaNADPH OxidasesInduction ChemotherapyMiddle Agedrac GTP-Binding ProteinsRac GTP-Binding ProteinsLeukemia Myeloid Acute030104 developmental biologychemistry030220 oncology & carcinogenesisToxicitybiology.proteinMolecular MedicineFemaleReactive Oxygen SpeciesThe pharmacogenomics journal
researchProduct

Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

2017

Abstract Context Angiopoietin-like 3 (ANGPTL3) deficiency in plasma due to loss-of-function gene mutations results in familial combined hypobetalipoproteinemia type 2 (FHBL2) in homozygotes. However, the lipid phenotype in heterozygotes is much milder and does not appear to relate directly to ANGPTL3 levels. Furthermore, the low-density lipoprotein (LDL) phenotype in carriers of ANGPTL3 mutations is unexplained. Objective To determine whether reduction below a critical threshold in plasma ANGPTL3 levels is a determinant of lipoprotein metabolism in FHBL2, and to determine whether proprotein convertase subtilisin kexin type 9 (PCSK9) is involved in determining low LDL levels in this conditio…

0301 basic medicineMaleApolipoprotein BEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryLipoprotein particlePCSK9Cohort StudiesHypobetalipoproteinemiaschemistry.chemical_compoundEndocrinologyANGPTL3biologyChemistryMiddle AgedPedigreeLipoproteins LDLPhenotypeKexinlipids (amino acids peptides and proteins)FemaleANGPTL3; familial combined hypolipidemia; PCSK9Lipoproteins HDLAdultmedicine.medical_specialtyHeterozygoteBlotting Western03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseClinical Research ArticlesAgedAngiopoietin-Like Protein 3Apolipoproteins BCholesterolPCSK9Biochemistry (medical)medicine.disease030104 developmental biologyEndocrinologyAngiopoietin-like ProteinsLDL receptorMultivariate AnalysisMutationbiology.proteinLinear Modelsfamilial combined hypobetalipoproteinemiaHypobetalipoproteinemiaAngiopoietinsLipoprotein
researchProduct

Treatment patterns for metastatic colorectal cancer in Spain

2020

Abstract Purpose The primary aim of this retrospective study was to describe the treatment patterns according to the type of treatment received by patients with metastatic colorectal cancer (mCRC) in Spain. Methods This was a retrospective, observational, multicenter study performed by 33 sites throughout Spain that included consecutive patients aged 18 years or older who had received or were receiving treatment for mCRC. Results At the time of inclusion, of the 873 evaluable patients, 507 (58%) had received two lines, 235 (27%) had received three lines, 106 (12%) had received four lines, and the remaining patients had received up to ten lines. The most frequent chemotherapy schemes were th…

0301 basic medicineMaleCancer ResearchColorectal cancermedicine.medical_treatmentmedicine.disease_causeTargeted therapy0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsKRAS/BRAF mutation statusMolecular Targeted TherapyNeoplasm MetastasisCàncerTreatment patternsGeneral MedicineMiddle AgedTreatment OutcomeOncology030220 oncology & carcinogenesisFOLFIRIMetastaticFemaleKRASGuideline AdherenceColorectal NeoplasmsCàncer Pacientsmedicine.drugResearch ArticleProto-Oncogene Proteins B-rafmedicine.medical_specialtyProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesClinical practice guidelineChemotherapybusiness.industryRetrospective cohort studymedicine.diseaseColorectal cancerdigestive system diseases030104 developmental biologySpainMutationObservational studybusiness
researchProduct